Sven Sondhauss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sven Sondhauss has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Brett Delahunt
Aquesta Uropathology, Toowong, Qld, Australia; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Malaghan Institute of Medical Research, Wellington, New Zealand
1 shared publication - David S. Lamb
University of Otago, Wellington, New Zealand
1 shared publication - John N. Nacey
Department of Surgery and Anaesthesia, University of Otago Wellington, Wellington, New Zealand
1 shared publication - Jonathan C. Dunne
Centre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington, PO Box 600, Wellington, New Zealand
1 shared publication - Judith Murray
Prostate Cancer Trials Unit, Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand
1 shared publication - Peter Bethwaite
Prostate Cancer Trials Unit, Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand
1 shared publication
Latest Publications
- Open Access
- 16 September 2015
- Published by Springer Nature in Clinical Proteomics
- Vol. 12 (1) , 1-10
Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease
Prostate cancer is the most frequently diagnosed cancer in men and the third leading cause of cancer related deaths among men living in developed countries. Biomarkers that predict disease outcome at the time of initial diagnosis would substantially aid disease management. Proteins extracted from formalin-fixed paraffin-embedded tissue were identified using nanoflow liquid chromatography-MALDI MS/MS or after separation by one- or two-dimensional electrophoresis. The proteomics data have been deposited to the ProteomeXchange with identifier PXD000963. A list of potential biomarker candidates, based on proposed associations with prostate cancer, was derived from the 320 identified proteins. Candidate biomarkers were then examined by multiplexed Western blotting of archival specimens from men with premetastatic disease and subsequent disease outcome data. Annexin A2 provided the best prediction of risk of metastatic disease (log-rank Chi squared p = 0. 025). A tumor/control tissue >2-fold relative abundance increase predicted early biochemical failure, while <2-fold change predicted late or no biochemical failure. This study confirms the potential for use of archival FFPE specimens in the search for prognostic biomarkers for prostate cancer and suggests that annexin A2 abundance in diagnostic biopsies is predictive for metastatic potential. Protein profiling each cancer may lead to an overall reduction in mortality from metastatic prostate cancer as well as reduced treatment associated morbidity.
- 16 September 2015
- Published by Springer Nature in Clinical Proteomics
- Vol. 12 (1) , 1-10
Open AccessProteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease
Prostate cancer is the most frequently diagnosed cancer in men and the third leading cause of cancer related deaths among men living in developed countries. Biomarkers that predict disease outcome at the time of initial diagnosis would substantially aid disease management. Proteins extracted from formalin-fixed paraffin-embedded tissue were identified using nanoflow liquid chromatography-MALDI MS/MS or after separation by one- or two-dimensional electrophoresis. The proteomics data have been deposited to the ProteomeXchange with identifier PXD000963. A list of potential biomarker candidates, based on proposed associations with prostate cancer, was derived from the 320 identified proteins. Candidate biomarkers were then examined by multiplexed Western blotting of archival specimens from men with premetastatic disease and subsequent disease outcome data. Annexin A2 provided the best prediction of risk of metastatic disease (log-rank Chi squared p = 0. 025). A tumor/control tissue >2-fold relative abundance increase predicted early biochemical failure, while <2-fold change predicted late or no biochemical failure. This study confirms the potential for use of archival FFPE specimens in the search for prognostic biomarkers for prostate cancer and suggests that annexin A2 abundance in diagnostic biopsies is predictive for metastatic potential. Protein profiling each cancer may lead to an overall reduction in mortality from metastatic prostate cancer as well as reduced treatment associated morbidity.